Other Medical products:
- EN14683:2019 type II medical face masks
- 1 ml syringes for COVID-19 Vaccine
GaDia is developing rapid tests for hospital and healthcare centers in the field of infectious diseases
Infections in hospital can quickly be life-threatening. Actual tests are mostly based on the microbial analysis and are time-consuming. With the solution developed by GaDia, physicians can rapidly select the right treatment and save time.
Because time matters !
Fungal Infections
Globally, over 300 million of people suffer from serious fungal infections every year with 1.6 million of deaths. Many deaths caused by fungal infections are avoidable with a rapid diagnostic and the right treatment.
Our first rapid test is intended to be used as first line screening test in hospital for patients with suspected Candida sp. fungal infections.
Our patented test differentiates Candida fungal infections from other causes of infection and gives a result in 15 minutes to start the right treatment.
Characteristics of the test
CandiDia is the first rapid immunochromatographic test for the early diagnostic of patients affected by invasive candidiasis and candidemia.
| Human Fluid | Blood, serum or plasma Bronchoalveolar lavage (BAL) |
| Test principle | IgG against a patented combination of fungal biomarkers |
| Diagnostic performances (consult IFU for more information) |
Sensitivity: 95% (IC95: 73-100%) Specificity: 83% (IC95: 61-94%) |
| Storage | 5-25°C |
| Availability |
2021 |
CandiDia_Flyer_v1.0
Buy Now
Our rapid test detects specific hyphal antigen from Aspergillus sp. in serum or Bronchoalveolar lavage (BAL) in only 15 minutes. More than 300’000 people are affected by Invasive Aspergilosis each year with high mortality rate without a rapid diagnostic and treatment. Detection of Galactomannan antigen in BAL or Serum is recommanded for the diagnosis of invasive Aspergilosis (ESCMID-ECMM-ERS guidelines 2017).
.
Characteristics of the test
| Human Fluid | Serum or plasma Bronchoalveolar lavage (BAL) |
| Test principle | Detection of Aspergillus specific hyphal antigen |
| Diagnostic performances (on BAL samples, consult IFU for more information) |
Sensitivity: 90.3% (IC95: 82.9-94.8%) Specificity: 92.5% (IC95: 87.8-95.6%) |
| Storage | 5-25°C |
| Availability |
2021, CE-IVD |
Flyer Aspergillus Ag
Buy Now
Our rapid immunechromatographic assay detects of the capsular polysaccharide antigens of Cryptococcus sp. complex (Cryptococcus neoformans and Cryptococcus gattii) in serum, plasma, whole blood and cerebral spinal fluid (CSF)
Characteristics of the test
| Human Fluid | Whole blood, Serum or plasma Cerebral spinal fluid (CSF) |
| Test principle | Detection of Cryptococcus sp. capsular antigen |
| Diagnostic performances (on CSF samples, consult IFU for more information) |
Sensitivity: 99.9% (IC95: 96.6-100%) Specificity: 99.1% (IC95: 97.1-99.8%) |
| Storage | 5-25°C |
| Availability |
2021, CE-IVD |
Flyer Cryptococcal Ag
Buy Now
Viral Infections
Viral Infections are among the leading causes of deaths due in adults living in low and middle income countries. Treatment for these diseases exists, but their effectiveness face numerous challenges including timely diagnosis.
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2, a new strain of coronavirus that has not been previously identified in human. Detection of SARS-CoV-2 IgM and IgG antibodies in human blood can be used as an auxiliary screening tool of COVID-19 infected patients.
PRINCIPLE
The test detects the IgM and IgG specific to nucleocapsid protein (N protein) and spike protein (S protein).
The test was evaluated at University Hospital of Geneva (HUG) and Lausanne (CHUV) in Switzerland.
ORDER
MORE INFORMATION
Simtomax CoronaCheck_flyer_v7.0
Clinical study at University Hospital Geneva (HUG)
Clinical study at University of Applied Sciences (HES-SO)
COVID-19 Rapid test development
Rapid diagnostic test for the detection of Nucleocapsid antigen in Nasopharyngeal swab of COVID-19 suspected patients. The test has been validated for the rapid and easy detection of SARS-CoV-2 antigen in saliva.
Made in Switzerland
Characteristics of the test
| Human Fluid | Nasopharyngeal Swabs, Nasal swabs |
| Test principle | Detection of Nucleocapsid antigen |
|
Diagnostic performances Ref. Ducrest et al. 2021, medRxiv |
Sensitivity: 90.0% (IC95: 81.2-100%) Sensitivity (CT<30): 100% |
| Storage | 5-30°C |
| Availability |
2021 |